MedTrace Logo

Relapse Prevention for Suicidal Dually Diagnosed Youths

NCT00589641 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2014-07-10

No results posted yet for this study

Summary

The purpose of this study is to develop, refine, and pilot test an augmenting cognitive behavior relapse prevention intervention (CBT-RP) for suicidal, depressed, and alcohol/substance abusing adolescents. No hypotheses are being tested, but it is expected that CBT-RP in addition to treatment as usual will result in improved outcomes relative to treatment as usual alone.

Conditions

Interventions

BEHAVIORAL

CBT-RP (relapse prevention) + Enhanced TAU

CBT-RP is an 20-week augmenting intervention. CBT-RP is based primarily on Alan Marlatt's cognitive behavioral relapse prevention model for substance abuse, but also includes motivational interviewing and mindfulness meditation approaches. Sessions are twice a week in first week, then weekly thereafter, with tapering to biweekly in the last 8 weeks depending on improvement. Participants also receive treatment as usual, and monthly check-ins regarding treatment use.

BEHAVIORAL

Enhanced TAU Alone

Treatment as usual in the community, monthly check-ins regarding treatment use or needs, and monitoring

Sponsors & Collaborators

  • UConn Health

    collaborator OTHER

  • University of North Carolina, Chapel Hill

    collaborator OTHER

  • University of North Carolina, Greensboro

    collaborator OTHER

  • Duke University

    lead OTHER

Principal Investigators

  • David B Goldston, Ph.D. · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2010-09-30
Completion
2010-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00589641 on ClinicalTrials.gov